A novel complete-case analysis to determine statistical significance between treatments in an intention-to-treat population of randomized clinical trials involving missing data

Abstract

The application of the principle of the intention-to-treat (ITT) to the analysis of clinical trials is challenged in the presence of missing outcome data. The consequences of stopping an assigned treatment in a withdrawn subject are unknown. It is difficult to make a single assumption about missing mechanisms for all clinical trials because there are complicated reactions in the human body to drugs due to the presence of complex biological networks, leading to data missing randomly or non-randomly. Currently there is no statistical method that can tell whether a difference between two treatments in the ITT population of a randomized clinical trial with missing data is significant at a pre-specified level. Making no assumptions about the missing mechanisms, we propose a generalized complete-case (GCC) analysis based on the data of completers. An evaluation of the impact of missing data on the ITT analysis reveals that a statistically significant GCC result implies a significant treatment effect in the ITT population at a pre-specified significance level unless, relative to the comparator, the test drug is poisonous to the non-completers as documented in their medical records. Applications of the GCC analysis are illustrated using literature data, and its properties and limits are discussed.

Keywords

Drug toxicity benefit–risk medical information impact of missing data inferential analysis

Get full access to this article

View all access options for this article.

References

Lachin

. Statistical considerations in the intent-to-treat principle. Control Clin Trials 2000; 21: 167–189.

Fisher

Dixon

Herson

et al.

Intent to treat in clinical trials. In: Peace

(ed). Statistical issues in drug research and development, New York, NY: Mercel Dekker, Inc, 1990, pp. 331–350.

Gupta

. Intention-to-treat concept: a review. Perspect Clin Res 2011; 2: 109–109.

O’Neill

Temple

. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther 2012; 91: 550–554.

Pocock

Abdalla

. The hope and the hazards of using compliance data in randomized controlled trials. Stat Med 1998; 17: 303–317.

Armijo-Olivo

Warren

Magee

. Intention to treat analysis, compliance, drop-outs and how to deal with missing data in clinical research: a review. Phys Ther Rev 2009; 14: 36–49.

Enders

. Applied missing data analysis, New York, NY: Guilford Publications, 2010.

Carpenter

Kenward

Vansteelandt

. A comparison of multiple imputation and doubly robust estimation for analyses with missing data. J R Stat Soc Series A (Stat Soc) 2006; 169: 571–584.

Donders

ART

van der Heijden

Stijnen

et al.

Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006; 59: 1087–1091.

10.

Bombardier

Tugwell

. Controversies in the analysis of long term clinical trials of slow acting drugs. J Rheumatol 1985; 12: 403–405.

11.

Rubin

. Inference and missing data. Biometrika 1976; 63: 581–592.

12.

Dziura

Post

Zhao

et al.

Strategies for dealing with missing data in clinical trials: from design to analysis. Yale J Biol Med 2013; 86: 343–358.

13.

National Research Council. The prevention and treatment of missing data in clinical trials. Washington, DC: National Academies Press, 2010.

14.

Little

D’Agostino

Cohen

et al.

The prevention and treatment of missing data in clinical trials. N Engl J Med 2012; 367: 1355–1360.

15.

Kitano

. Systems biology: a brief overview. Science 2002; 295: 1662–1664.

16.

Guimera

Amaral

LAN

. Functional cartography of complex metabolic networks. Nature 2005; 433: 895–900.

17.

Gibson

Skett

. Introduction to drug metabolism, Cheltenham, UK: Nelson Thornes, 2001.

18.

Fry

. Sepsis, systemic inﬂammatory response, and multiple organ dysfunction: the mystery continues. Am Surg 2012; 78: 1–8.

19.

Hotchkiss

Swanson

Freeman

et al.

Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27: 1230–1251.

20.

Tilghman

Nierth-Simpson

Wallace

et al.

Environmental hormones: multiple pathways for response may lead to multiple disease outcomes. Steroids 2010; 75: 520–523.

21.

Chen

. Assessing clinically relevant treatment differences using weighted responder means. Model Assist Stat Appl 2010; 5: 159–167.

22.

Schoedel

Meier

Chakraborty

et al.

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users. Clin Pharmacol Ther 2010; 88: 69–78.

23.

Gallwitz

Rosenstock

Rauch

et al.

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. The Lancet 2012; 380: 475–483.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.25 MB